These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Evidence for neuroprotective effects of antipsychotic drugs: implications for the pathophysiology and treatment of schizophrenia. Li XM; Xu H Int Rev Neurobiol; 2007; 77():107-42. PubMed ID: 17178473 [No Abstract] [Full Text] [Related]
24. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Guillin O; Demily C; Thibaut F Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867 [TBL] [Abstract][Full Text] [Related]
28. [Neurobiology in the neuropharmacology of antipsychotic drugs]. Tassin JP Encephale; 2006 Jan; 32 Pt 2():S6-7. PubMed ID: 16800077 [No Abstract] [Full Text] [Related]
29. Biological underpinnings of treatment resistance in schizophrenia: an hypothesis. Bartzokis G; Altshuler L Psychopharmacol Bull; 2003; 37(4):5-7. PubMed ID: 15272475 [No Abstract] [Full Text] [Related]
30. The quantitative neuropathology of schizophrenia. Hof PR; Schmitz C Acta Neuropathol; 2009 Apr; 117(4):345-6. PubMed ID: 19247680 [No Abstract] [Full Text] [Related]
31. The complexity of the dopaminergic synapses and their modulation by antipsychotics. Leuner K; Müller WE Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891 [TBL] [Abstract][Full Text] [Related]
32. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Kondziella D; Brenner E; Eyjolfsson EM; Sonnewald U Neurochem Int; 2007 Jan; 50(2):291-301. PubMed ID: 17084946 [TBL] [Abstract][Full Text] [Related]
33. The neurobiology of cognition in schizophrenia. Tamminga CA J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078 [TBL] [Abstract][Full Text] [Related]
34. [Preliminary study of schizophrenics with brain atrophy treated with antipsychotic drugs]. Wang XY Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1988 Oct; 21(5):294-6, 319. PubMed ID: 2906857 [No Abstract] [Full Text] [Related]
35. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Hajós M Trends Pharmacol Sci; 2006 Jul; 27(7):391-8. PubMed ID: 16766049 [TBL] [Abstract][Full Text] [Related]
36. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder. Gogos JA Int Rev Neurobiol; 2007; 78():397-422. PubMed ID: 17349868 [TBL] [Abstract][Full Text] [Related]
37. Chemical and physiologic brain imaging in schizophrenia. McClure RJ; Keshavan MS; Pettegrew JW Psychiatr Clin North Am; 1998 Mar; 21(1):93-122. PubMed ID: 9551493 [TBL] [Abstract][Full Text] [Related]
38. Recent advances in the pharmacotherapy of schizophrenia. Lapierre YD Psychiatr J Univ Ott; 1983 Jun; 8(2):81-5. PubMed ID: 6137017 [No Abstract] [Full Text] [Related]
39. Dopamine neuronal tracts in schizophrenia: their pharmacology and in vivo glucose metabolism. Tamminga CA; Burrows GH; Chase TN; Alphs LD; Thaker GK Ann N Y Acad Sci; 1988; 537():443-50. PubMed ID: 2904785 [No Abstract] [Full Text] [Related]